Cargando…

Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model

Background. Cell-free DNA circulates in cancer patients and induces in vivo cell transformation and cancer progression in susceptible cells. Based on this, we hypothesized that depletion of circulating DNA with DNAse I and a protease mix could have antitumor effects. Study design. The study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trejo-Becerril, Catalina, Pérez-Cardenas, Enrique, Gutiérrez-Díaz, Blanca, De La Cruz-Sigüenza, Desiree, Taja-Chayeb, Lucía, González-Ballesteros, Mauricio, García-López, Patricia, Chanona, José, Dueñas-González, Alfonso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	E-Only Section
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739158/ https://www.ncbi.nlm.nih.gov/pubmed/27146129 http://dx.doi.org/10.1177/1534735416631102

Ejemplares similares

Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells
por: Pérez-Cárdenas, Enrique, et al.
Publicado: (2018)

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
por: Zambrano, Pilar, et al.
Publicado: (2005)

Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance
por: Trejo-Becerril, Catalina, et al.
Publicado: (2005)

Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome
por: Taja-Chayeb, Lucia, et al.
Publicado: (2009)

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006)

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
por: Chavez-Blanco, Alma, et al.
Publicado: (2005)

Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine
por: Segura-Pacheco, Blanca, et al.
Publicado: (2006)

Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer
por: Taja-Chayeb, Lucia, et al.
Publicado: (2006)

DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells
por: Candelaria, Myrna, et al.
Publicado: (2012)

Hydralazine target: From blood vessels to the epigenome
por: Arce, Claudia, et al.
Publicado: (2006)

Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIB. A phase II study
por: Candelaria, Myrna, et al.
Publicado: (2007)

Immune Cell–Conditioned Media Suppress Prostate Cancer PC-3 Cell Growth Correlating With Decreased Proinflammatory/Anti-inflammatory Cytokine Ratios in the Media Using 5 Selected Crude Polysaccharides
por: Lin, Hsiao-Chien, et al.
Publicado: (2016)

Evaluation of Antiangiogenic Efficacy of Emilia sonchifolia (L.) DC on Tumor-Specific Neovessel Formation by Regulating MMPs, VEGF, and Proinflammatory Cytokines
por: Gilcy, George K, et al.
Publicado: (2016)

Deoxyrhapontigenin, a Natural Stilbene Derivative Isolated From Rheum undulatum L. Induces Endoplasmic Reticulum Stress–Mediated Apoptosis in Human Breast Cancer Cells
por: Venkatesan, Thamizhiniyan, et al.
Publicado: (2016)

Chemopreventive Activity of MGN-3/Biobran Against Chemical Induction of Glandular Stomach Carcinogenesis in Rats and Its Apoptotic Effect in Gastric Cancer Cells
por: Badr El-Din, Nariman K., et al.
Publicado: (2016)

The Antimetastatic and Antiangiogenesis Effects of Kefir Water on Murine Breast Cancer Cells
por: Zamberi, Nur Rizi, et al.
Publicado: (2016)

E-Only Section
Publicado: (2016)

Cancer Progression Mediated by Horizontal Gene Transfer in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2012)

A proof-of-principle study of epigenetic therapy with hydralazine and magnesium valproate plus doxorubicin cyclophosphamide as neoadjuvant therapy for locally advanced breast cancer
por: Arce, Claudia, et al.
Publicado: (2007)

A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
por: Arce, Claudia, et al.
Publicado: (2006)

Molecular characterization of BRCA1 and BRCA2 genes in breast cancer patients under 40 years-old or with familiar cancer history
por: Millan, Silvia Vidal, et al.
Publicado: (2007)

Polymorphisms of the thiopurine methyl transferase gene in healthy and acute lymphoblastic leukemia mestizos
por: Candelaria, Myrna, et al.
Publicado: (2007)

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
por: Candelaria, Myrna, et al.
Publicado: (2007)

Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes
por: Martin, Roman, et al.
Publicado: (2018)

PB2609: 14 YEARS OF EXPERIENCE WITH THROMBOPOIETIN RECEPTOR AGONISTS IN A SINGLE CENTER
por: Garcia-Pallarols, Francesc, et al.
Publicado: (2023)

PB2665: THROMBOTIC PROFILE OF A SERIE OF 14 PATIENTS CARRYING 67ARG>STOP POLYMORPHISM IN THE SERPINE A10 (PROTEASE-DEPENDENT PROTEIN Z INHIBITOR) GENE
por: Bermejo, Nuria, et al.
Publicado: (2023)

A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells
por: Schcolnik-Cabrera, Alejandro, et al.
Publicado: (2020)

PB2616: SYSTEMIC LUPUS ERYTHEMATOSUS RELATED IMMUNE THROMBOCYTOPENIA: A CHARACTERISTIC CLINICAL FENOTIPE
por: Cornudella, Jesus, et al.
Publicado: (2023)

Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open-label, 6-month extension study
por: Vadhan-Raj, Saroj, et al.
Publicado: (2016)

Genetic variants at HbF‐modifier loci moderate anemia and leukocytosis in sickle cell disease in Tanzania
por: Mtatiro, Siana Nkya, et al.
Publicado: (2014)

Treatment of central venous catheter‐associated deep venous thrombosis in cancer patients with rivaroxaban
por: Laube, Eva S., et al.
Publicado: (2016)

Development of cellular and humoral response against WT1 protein vaccination in mice
por: Nicoli, Paolo, et al.
Publicado: (2015)

Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid‐directed monoclonal antibody
por: gertz, morie a., et al.
Publicado: (2016)

A second retrospective database analysis confirms prior findings of apparent increased cardiovascular comorbidities in hemophilia A in the United States
por: Humphries, Thomas J., et al.
Publicado: (2016)

Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
por: Chyla, Brenda, et al.
Publicado: (2018)

Hemoglobin response to ferric citrate in patients with nondialysis‐dependent chronic kidney disease and iron deficiency anemia
por: Pergola, Pablo E., et al.
Publicado: (2018)

The effect of azacitidine therapy on the M protein of MDS patients with concomitant MGUS
por: Oka, Satoko, et al.
Publicado: (2018)

Iron overload in patients with rare hereditary hemolytic anemia: Evidence‐based suggestion on whom and how to screen
por: van Straaten, Stephanie, et al.
Publicado: (2018)

Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2018)

Influence of patient‐reported outcomes on the treatment effect of deferasirox film‐coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis
por: Taher, Ali T., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nr29eeguek8mt6e1rmkh08j4hr